Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm
Viruses · 2023
DOI: 10.3390/v15102036 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Viruses, 2023. Verfasst von Lesley E Jackson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35233, USA. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, University of Alabama at Birmingham School of Medicine (UABSOM) COVID-19, Swedish Orphan Biovitrum (SOBI).
Abstract (Originalsprache)
(1)
Background
Some severe COVID-19 patients develop hyperinflammatory cytokine storm syndrome (CSS). We assessed the efficacy of anakinra added to standard of care (SoC) in hospitalized COVID-19 CSS patients. (2)
Methods
In this single-center, randomized, double-blind, placebo-controlled trial (NCT04362111), we recruited adult hospitalized patients with SARS-CoV-2 infection, evidence of pneumonia, new/increasing oxygen requirement, ferritin ≥ 700 ng/mL, and at least three of the following indicators: D-dimer ≥ 500 ng/mL, platelet count < 130,000/mm3, WBC < 3500/mm3 or lymphocyte count < 1000/mm3, AST or ALT > 2X the upper limit of normal (ULN), LDH > 2X ULN, C-reactive protein > 100 mg/L. Patients were randomized (1:1) to SoC plus anakinra (100 mg subcutaneously every 6 h for 10 days) or placebo. All received dexamethasone. The primary outcome was survival and hospital discharge without need for intubation/mechanical ventilation. The data were analyzed according to the modified intention-to-treat approach. (3)
Results
Between August 2020 and January 2021, 32 patients were recruited, of which 15 were assigned to the anakinra group, and 17 to the placebo group. Two patients receiving the placebo withdrew within 48 h and were excluded. The mean age was 63 years (SD 10.3), 20 (67%) patients were men, and 20 (67%) were White. At Day 10, one (7%) patient receiving anakinra and two (13%) patients receiving the placebo had died (p = 1.0). At hospital discharge, four (27%) patients receiving anakinra and four (27%) patients receiving the placebo had died. The IL-6 level at enrollment was predictive of death (p < 0.01); anakinra use was associated with decreases in CXCL9 levels. (4)
Conclusions
Anakinra added to dexamethasone did not significantly impact the survival of COVID-19 pneumonia patients with CSS. Additional studies are needed to assess patient selection and the efficacy, timing, and duration of anakinra treatment for COVID-19 CSS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
- Children's of Alabama, Birmingham, AL 35233, USA.
- UAB Hospital Pharmacy, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
- Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
ORCID-Profile: Lesley E Jackson, Abhishek Kamath, Randy Q Cron
Förderung
- NIAMS NIH HHS
- University of Alabama at Birmingham School of Medicine (UABSOM) COVID-19
- Swedish Orphan Biovitrum (SOBI)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Jackson, L. E., Khullar, N., Beukelman, T., Chapleau, C., Kamath, A., Cron, R. Q., & Chatham, W. W. (2023). Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm. Viruses. https://doi.org/10.3390/v15102036
Vancouver
Jackson LE, Khullar N, Beukelman T, Chapleau C, Kamath A, Cron RQ, et al. Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm. Viruses. 2023. doi:10.3390/v15102036
BibTeX
@article{Jackson2023,
author = {Jackson, Lesley E and Khullar, Nitasha and Beukelman, Timothy and Chapleau, Chris and Kamath, Abhishek and Cron, Randy Q and Chatham, Walter Winn},
title = {Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15102036}
}
EUVIMED